TP-1287

• UNSPSC Description:

  TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active CDK9 inhibitor[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tp-1287.html

• Solubility:

  DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C)|Methanol : 125 mg/mL (ultrasonic)

• Smiles:

  O=P(O)(O)OC1=CC(O)=C(C(C=C(C2=C(C=CC=C2)Cl)O3)=O)C3=C1[C@@H]4[C@@H](CN(CC4)C)O

• Molecular Weight:

  481.82

• References & Citations:

  [1]Tyagi E, et al. The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma. Blood, 2018, 132: 3269.|[2]Kim W, et al. TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib. Cancer Research, 2017, 77(13_Supplement): 5133-5133.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Phase 1

• CAS Number:

  2044686-42-0